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Major Depression Symptoms in Primary 
Care and Psychiatric Care Settings: 
A Cross-Sectional Analysis
ABSTRACT
PURPOSE We undertook a study to confi rm and extend preliminary fi ndings that 
participants with major depressive disorder (MDD) in primary care and specialty 
care settings have with equivalent degrees of depression severity and an indistin-
guishable constellation of symptoms. 
METHODS Baseline data were collected for a distinct validation cohort of 
2,541 participants (42% primary care) from 14 US regional centers comprised 
of 41 clinic sites (18 primary care, 23 specialty care). Participants met broadly 
inclusive eligibility criteria requiring a Diagnostic and Statistical Manual of Mental 
Disorders, Fourth Edition, diagnosis of MDD and a minimum depressive symptom 
score on the 17-item Hamilton Rating Scale for Depression. The main outcome 
measures were the 30-item Inventory of Depressive Symptomatology – Clinician 
Rated and the Psychiatric Diagnostic Screening Questionnaire.
RESULTS Primary care and specialty care participants had identical levels of mod-
erately severe depression and identical distributions of depressive severity scores. 
Both primary care and specialty care participants showed considerable suicide risk, 
with specialty care participants even more likely to report prior suicide attempts. 
Core depressive symptoms or concurrent psychiatric disorders were not substantially 
different between settings. One half of participants in each setting had an anxiety 
disorder (48.6% primary care vs 51.6% specialty care, P = .143), with social phobia 
being the most common (25.3% primary care vs 32.1% specialty care, P = .002). 
CONCLUSIONS For outpatients with nonpsychotic MDD, depressive symptoms 
and severity vary little between primary care and specialty care settings. In this 
large, broadly inclusive US sample, the risk factors for chronic and recurrent 
depressive illness were frequently present, highlighting a clear risk for treatment 
resistance and the need for aggressive management strategies in both settings. 
Ann Fam Med 2007;5:126-134. DOI: 10.1370/afm.641.
INTRODUCTION
S
ince the advent of newer antidepressants during the last 2 decades, 
primary care physicians have played a greater role in the management 
of depressive illness. According to data from the National Disease 
and Therapeutic Index Survey, the proportion of depression-related clinic 
visits made to primary care clinicians increased from 50% in 1987 to 64% in 
2001, and depressed patients are more likely to see a primary care physician 
than a mental health specialist for both diagnosis and treatment.1,2 Accord-
ingly, government guidelines about depression treatment in primary care 
are a key area of public policy,3,4 with its import highlighted by the current 
controversy over the safety of newer antidepressants.5-7 
Conventional wisdom has held that depressed patients in primary 
care settings are less severely depressed,8-10 experience a milder course 
of illness,8,11,12 have a distinct symptom profi le with more complaints of 
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fatigue13 and somatic symptoms,8 and are more likely 
to have accompanying physical complaints8,14,15 than 
depressed patients seeking psychiatric specialty care. 
Our earlier report from the Sequenced Treatment 
Alternatives to Relieve Depression (STAR*D) study 
(http://www.star-d.org), which was based on the fi rst 
1,500 enrolled participants, directly compared par-
ticipants concurrently enrolled from primary care and 
specialty care settings and found their levels of depres-
sion, distributions of total depressive severity, and 
symptoms to be remarkably similar.16 Some differences 
did emerge in that report. Specialty care participants 
were nearly twice as likely to have made a prior suicide 
attempt, and although nearly one half of participants 
from each setting endorsed suicidal ideation in the 
past, it was more common in specialty care patients. 
We now report on a subsequent and distinct sample, 
the remaining 2,541 participants who enrolled in 
STAR*D from primary care or specialty care settings. 
Given the broadly inclusive eligibility criteria and lim-
ited exclusion criteria (see below), fi ndings should be 
generalizable to most patients who seek treatment for 
nonpsychotic major depressive disorder (MDD) in pri-
mary care or specialty care settings. In this report we 
aim to (1) confi rm our initial fi ndings regarding baseline 
sociodemographic and clinical features of primary care 
and specialty care patients, and (2) extend our fi ndings 
by reporting on concurrent psychiatric conditions. 
METHODS
Study Description and Organization
The rationale and design of STAR*D are detailed 
elsewhere.17,18 Briefl y, the purpose of STAR*D was to 
defi ne prospectively which of several treatments are 
most effective for outpatients with nonpsychotic MDD 
who have unsatisfactory initial and, if necessary, subse-
quent clinical treatment outcomes. The STAR*D par-
ticipants were enrolled at 18 primary care and 23 spe-
cialty care settings across the United States, with adver-
tising for symptomatic volunteers being proscribed. 
Both primary care and specialty care sites that provided 
care to public and private sector patients were selected 
on the basis of having (1) suffi cient patient numbers, (2) 
suffi cient numbers of clinicians, (3) suffi cient adminis-
trative support, and (4) suffi cient numbers of racial/eth-
nic minority patients so that the study population could 
mirror the US Census and results would be widely 
generalizable. The median number of clinicians at the 
18 primary care sites was 14.5 compared with 12.0 at 
the 23 primary care sites. Three quarters of the facili-
ties were privately owned, and approximately two thirds 
were freestanding (ie, not hospital-based). 
The institutional review boards at the National 
Coordinating Center (Dallas), the Data Coordinating 
Center (Pittsburgh), and at each of 14 US regional cen-
ters (each of which oversaw the study at 2 to 4 clinical 
sites) approved the study protocol.
Study Population
Broadly inclusive selection criteria, described in detail 
elsewhere,17,18 were used to optimize generalizability 
of fi ndings to patients already being seen in outpatient 
settings. Briefl y, established outpatients, in either pri-
mary care or specialty care settings and identifi ed by 
their clinician as having a depression requiring treat-
ment, were asked to participate in STAR*D. All risks, 
benefi ts, and adverse events associated with the trial 
were explained to potential participants, who provided 
written informed consent before study participation. 
Eligible participants were aged 18 to 75 years, met Diag-
nostic and Statistical Manual of Mental Disorders, Fourth Edition 
(DSM-IV) criteria for single or recurrent nonpsychotic 
MDD, scored ≥14 (moderate severity) on the 17-item 
version of the Hamilton Rating Scale for Depression 
(HRSD17)19,20 as rated by the clinical research coordina-
tor, and were not resistant to an adequate antidepressant 
treatment trial during the current episode. Exclusion 
criteria included psychiatric illness requiring a different 
treatment approach (eg, bipolar disorder or psychotic 
symptoms), or a seizure disorder or other general medi-
cal condition that contraindicated medications used in 
the fi rst 2 protocol treatment steps. All other psychiatric 
and medical comorbidities were allowed. 
Measurements
At baseline, the clinical research coordinators col-
lected standard demographic information, self-
reported psychiatric history, and current general med-
ical conditions as evaluated by the Cumulative Illness 
Rating Scale (CIRS).21
Participants also completed the Psychiatric Diag-
nostic Screening Questionnaire (PDSQ),22,23 which 
consists of 126 yes/no items to assess symptoms of the 
13 various nonpsychotic DSM-IV disorders. Based on 
prior reports,22 we selected a scoring procedure and 
thresholds that yielded a 90% specifi city in relation to 
the reference standard diagnosis rendered by a struc-
tured interview (the Structured Clinical Interview for 
DSM-IV, or SCID).24 
The research outcomes assessor used a telephone 
interview25 at baseline to collect responses for the 
HRSD17 and the 30-item Inventory of Depressive 
Symptomatology (IDS-C30),26,27 a validated instrument 
that uses unconfounded items to measure both core cri-
terion diagnostic symptoms and associated symptoms. 
Because the results of these 2 were identical, we only 
report the latter.
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The Interactive Voice Response system28 was used 
to collect responses for health perceptions (the 12-Item 
Health Survey, or SF-1229), quality of life measures 
(Quality of Life Enjoyment and Satisfaction Question-
naire30), and the Work and Social Adjustment Scale 
(WSAS).31 
Data Analysis 
We compared continuous measures by setting using 
the appropriate parametric or nonparametric test. 
Using a χ2 test, we compared discrete variables across 
setting. We used multiple logistic regression models for 
dichotomous variables or analysis of covariance models 
for continuous variables to adjust the analyses for any 
demographic differences identifi ed, length of the cur-
rent episode, and number of general medical comor-
bidities (CIRS total score). P values ≤.05 were consid-
ered signifi cant in the above analyses. We performed 
no adjustments of P values for multiple comparisons, so 
results must be interpreted accordingly.
RESULTS
General
 We report on the fi nal 2,541 participants enrolled in 
STAR*D, which represented 92% of the 2,755 screened. 
Overall, 41.8% (n = 1,063) of enrolled participants came 
from primary care settings, whereas 58.2% (n = 1,478) 
came from specialty care settings. Compared with the 
prior sample, a larger proportion of the current sample 
was enrolled from primary care settings (42% of the 
current sample vs 34% of the prior sample; P <.001). 
Sociodemographic and Clinical Features
The overall levels of depressive symptom severity for 
primary care and specialty care participants were simi-
lar (IDS-C30: 35.2 in primary care and 35.4 in spe-
cialty care), and they refl ect a moderate-to-severe level 
of depressive symptoms. Furthermore, the distribution 
of total IDS-C30 scores did not differ between the 
2 settings (Figure 1). Sociodemographic differences 
are displayed in Table 1. Of note, primary care partici-
pants in this sample were more than twice as likely to 
be Hispanic. 
Course of Illness and Suicidal Risk
Primary care participants were older than specialty 
care participants at the onset of their fi rst depressive 
episode (median of 25 years primary care vs 19 years 
specialty care) and were less likely to have MDD begin 
before the age of 18 years (33.7% vs 47.2%; P <.001). 
Primary care participants reported a comparatively 
Figure 1. Distribution of IDS-C30 by setting.
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longer duration of their current major depressive 
episode (median of 10 months vs 6 months; P <.001). 
There was no difference in the length of illness (time 
from fi rst major depressive episode to study entry). 
Specialty care participants reported a greater 
likelihood of a history of attempted suicide than did 
primary care participants (18.1% vs 13.1%; P = <.001). 
Slightly more specialty care participants than primary 
care participants endorsed suicidal ideation in the 
previous week (ie, had thoughts within the week that 
life was not worth living: 51.4% vs 42.8%; adjusted P 
<.001 by IDS-C30). There was no difference between 
the proportions reporting a family history of suicide 
(2.7% of participants in each setting).
Current General Medical Conditions 
and Quality of Life 
 Compared with specialty care participants, primary care 
participants reported a greater total CIRS score (5.1 vs 
3.9; P <.001; Table 2). The most common comorbidi-
ties as indicated by a CIRS score ≥2 (indicating at least 
moderate disability) were musculoskeletal, including 
pain (24% primary care vs 14%; specialty care P <.001); 
vascular, including hypertension (23% primary care 
vs 12% specialty care; P <.001); endocrine/metabolic 
and breast, including diabetes (19% primary care vs 
9% specialty care; P <.001); and upper gastrointestinal 
(15% primary care vs 9% specialty care; P <.001). Other 
quality-of-life measures, while signifi cant, showed only 
slight differences. 
Depressive Symptoms 
We compared the individual items on the IDS-C30 for 
the 2 groups and adjusted by demographic differences, 
length of current depressive episode, and general medi-
cal condition total score. We calculated the proportion 
of participants in each group for whom the symptom was 
present (ie, rated ≥1) (this information is displayed in the 
Supplemental Table at http://www.annfammed.
org/cgi/content/full/5/2/126/DC1). We found bor-
derline signifi cant but largely clinically unimportant 
differences in symptom items of the essential mood 





n = 1,063 (41.8%)
Mean (SD)
Specialty Care




Mean (SD) P Value
HRSD17 (ROA) 19.6 (6.5) 19.7 (6.4) 19.6 (6.5) .839
IDS-C30 (ROA) 35.2 (11.6) 35.4 (11.3) 35.3 (11.4) .699
Age, years 43.7 (13.3) 38.2 (13.0) 40.5 (13.4) <.001
Years of schooling 12.8 (3.5) 13.8 (2.9) 13.4 (3.2) <.001
Race, %    .866
White 73.9 74.6 74.3  
Black or African American 17.6 16.8 17.1  
Others 8.5 8.6 8.6  
Ethnicity, Hispanic, % 22.0 9.3 14.6 <.001
Sex, female, % 68.0 59.0 62.8 <.001
Marital Status, %    <.001
Never married 25.3 34.6 30.7  
Married 42.9 39.4 40.8  
Divorced 26.1 24.2 25.0  
Widowed 5.7 1.8 3.5  
Employment status, %    .029
Unemployed 38.0 38.3 38.2  
Employed 55.1 57.2 56.3  
Retired 6.9 4.4 5.5  
Insurance Status, %    <.001
Private insurance 44.2 52.3 48.9  
Public insurance* 22.1 8.4 15.5  
No insurance 30.7 39.3 35.6  
Level of education, %    <.001
Less than completed college 80.1 72.6 75.7  
Completed college or more 19.9 27.4 24.3  
HRSD17 = 17-item Hamilton Rating Scale for Depression; ROA = research outcome assessor; IDS-C30: 30-item Inventory of Depressive Symptomatology, Clinician Rating.
* Public Insurance includes both Medicare and Medicaid.
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components: primary care participants tended to be less 
likely to complain of depressed mood (96.6% vs 97.6%; 
P = .053) and were slightly less likely to have anhedonia 
(80.6% vs 85.7%; P = .002). 
There were no signifi cant differences between the 
likelihood of having the core criterion symptoms of 
appetite or weight change, sleep disturbance, psycho-
motor slowing, loss of energy, or feeling worthless. As 
noted previously, specialty care participants were sig-
nifi cantly more likely to endorse suicidal ideation. Two 
other core symptoms showed a slight but signifi cant 
difference between the 2 settings: depressed specialty 
care participants were slightly more likely to endorse 
psychomotor agitation (64.5% vs 60.7%; P = .019) and 
decreased concentration (82.5% vs 76.6%; P = .008).
Psychiatric Comorbidities 
It was common in both settings for participants to have 
at least 1 comorbid psychiatric illness (Table 3 ), but 
it was slightly less common in primary care settings 
 (59.2% vs 64.1%; adjusted odds ratio (AOR), 1.31; P = 
.003). Approximately one half of participants in each 




n = 1,063 (41.8%)
Specialty Care








Mean (SE) Mean (SD)
Adjusted 
Mean (SE)
CIRS, total score 5.1 (4.1) – 3.9 (3.7) – 4.4 (3.9) <.001 –
SF-12        
Physical 46.4 (12.3) 47.6 (0.5) 51.1 (11.6) 49.5 (0.5) 49.2 (12.1) <.001 .004
Mental 28.9 (9.8) 28.7 (0.4) 25.5 (8.3) 26.2 (0.4) 26.9 (8.8) <.001 <.001
WSAS 22.3 (9.8) 21.8 (0.5) 24.4 (8.9) 24.2 (0.4) 23.5 (9.3) <.001 <.001
Q-LES-Q 42.7 (15.9) 44.0 (0.7) 41.0( 14.9) 41.2 (0.7) 41.7 (15.4) 0.013 <.001
CIRS = Cumulative Illness Rating Scale; SF-12 = 12-Item Health Survey; WSAS = Work and Social Adjustment Scale; Q-LES-Q = Quality of Life Enjoyment and 
Satisfaction Questionnaire.
* Adjusted for age, sex, education, marital status, employment status, ethnicity, length of current episode, and CIRS total score.
Table 3. Association of Primary/Specialty Setting With Psychiatric Comorbidities
Type and No. of Psychiatric 
Comorbidity
Primary Care






OR P Value OR P Value
Type of psychiatric comorbidity
Anxiety disorders 48.6 51.6 1.06 .143 1.23 .019
Social phobia 25.3 32.1 1.39 .001 1.37 .002
Generalized anxiety disorder 2.3 21.2 1.05 .604 1.26 .037
Posttraumatic stress disorder 16.5 17.6 1.08 .494 1.26 .054
Obsessive compulsive disorder 15.1 13.4 0.87 .228 0.96 .755
Panic 14.5 11.1 0.74 .012 0.88 .333
Agoraphobia 12.2 11.7 0.96 .729 1.33 .046
Nonanxiety disorders 29.3 33.0 1.13 .051 1.21 .043
Alcohol abuse 1.4 13.1 1.30 .044 1.21 .411
Drug abuse 6.0 9.1 1.57 .005 1.22 .245
Somatoform 3.0 1.8 0.59 .05 0.98 .947
Hypochondriasis 6.1 3.3 0.52 .001 0.79 .285
Bulimia 1.8 13.4 1.27 .056 1.36 .025






No. of psychiatric comorbidities
Mean 1.4 1.5 .041 .002
Median 1.0 1.0 ns ns
ns = not signifi cant.
* Adjusted for age, sex, education, employment status, marital status, ethnicity, length of current episode and CIRS (total score).
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setting had an anxiety disorder (48.6% in primary care 
vs 51.6% in specialty care; AOR, 1.23; P = .019), while 
approximately one third in each setting had a disorder 
other than an anxiety disorder (29.3% in primary care, 
33.0% in specialty care; AOR, 1.21; P = .043). The 
average number of comorbidities was similar between 
settings. 
In each setting, the most common single comorbid-
ity was social phobia, which was less likely in primary 
care settings (25.3% vs 32.1%; AOR, 1.37; P = .002). 
The remaining anxiety comorbidities showed less dif-
ference, with generalized anxiety disorder slightly 
more common in specialty care settings and agorapho-
bia slightly more common in primary care settings. Of 
the non−anxiety-disorder comorbidities, bulimia was 
the only one for which the likelihood of comorbidity 
differed by setting; it was more common in specialty 
care settings (13.4% vs 10.8%; AOR, 1.36; P = .025). 
DISCUSSION
These results, which represent the largest direct com-
parison of depressed primary care and specialty care 
patients ever conducted, strongly confi rm the fi ndings 
from our initial, separate cohort analysis. Among the 
fi nal 2,541 participants enrolled in STAR*D, those 
from primary care and specialty care settings with 
nonpsychotic MDD had equivalent degrees of depres-
sive severity and an identical distribution of total 
depression severity scores. The moderate degree and 
range of depressive severity we found is consistent 
with the level seen in previous primary care clinical tri-
als with more restrictive eligibility criteria.32-34 In addi-
tion, the specifi c depressive symptoms did not appear 
to differ substantially between the 2 settings. These 
fi ndings further challenge the conventional wisdom 
that primary care patients with major depressive illness 
requiring treatment are less depressed. Our fi ndings 
are consistent with our earlier STAR*D fi ndings of 
equivalent depressive symptoms and confi rm a con-
sistent trend across a broad range of sites. Our initial 
results were neither chance fi ndings nor a selection 
bias refl ecting a study in start-up mode. Such confi rma-
tion is important given the risk of contradictory and 
initially stronger effects seen in clinical research.35,36
Furthermore, these results are generalizable to 
the real-world practice setting in the United States 
for patients identifi ed as needing treatment of MDD 
and who agree to antidepressant medication. The 
characteristics of the patient population (predomi-
nantly white, female, employed, married, and privately 
insured, with approximately one fi fth receiving public 
insurance) correspond to those reported for adult out-
patients being seen for depression in the United States 
in the nationally representative samples assessed in 
the National Ambulatory Medical Care Survey37 and 
the National Medical Expenditure Survey.38 The fre-
quent medical and psychiatric comorbidities similarly 
make this population more representative of depressed 
patients seen for care.39-41
The specifi c depressive symptoms in each setting 
were essentially equivalent. Although primary care 
participants were slightly less likely report anhedonia, 
this difference is of questionable clinical importance, 
given that 97% from each setting had depressed 
mood, the other essential feature. Also, only 2 core 
symptoms—psychomotor agitation and decreased con-
centration—showed a slight but signifi cantly greater 
likelihood in specialty care settings. These fi ndings 
suggest substantial similarity between symptomatic 
depressive patients and reinforce our earlier fi ndings. 
As with earlier studies making a comparison 
between the 2 settings from an epidemiological10, 42 and 
a managed care42 perspective, depressed primary care 
patients were slightly older, had fewer years of school-
ing, were more likely to be African American, were 
more likely to be female, and were less likely to be 
employed. Our fi ndings reproduce and extend these 
reported sociodemographic differences to a greater 
variety of clinical settings.
Our results also confi rm and underscore that risk 
factors for suicidality, such as prior attempts and recent 
suicidal ideation,43 are common in both primary care 
and specialty care settings, although signifi cantly more 
likely in specialty care settings. In addition, our results 
confi rm that patients in specialty care clinics were more 
likely to have their fi rst depressive illness before the age 
of 18 years. Both suicidality and chronicity, then, appear 
as key variables increasing the likelihood of accessing 
psychiatric clinics for depression management.
Our fi ndings extend the similarity of depressive 
symptoms to include psychiatric comorbidity. Well 
more than one half of depressed participants in each 
setting had a comorbid psychiatric illness, usually an 
anxiety disorder, which was slightly more common 
in a specialty care setting. The 50% rate of comorbid 
anxiety disorders is consistent with reports from com-
munity settings,44 psychiatric outpatient clinics,45,46 and 
primary care populations.47,48 This high rate of psychi-
atric comorbidity in each setting is important because 
psychiatric comorbidity is a strong predictor of persis-
tent and recurrent depression.47,49
This study has a number of limitations. First, 
STAR*D clinics were not based on a random sam-
pling of primary care and specialty care clinics in the 
United States; clinical sites were selected based on 
the availability of patients, clinicians, and administra-
tive support. Still, the racial and ethnic composition 
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approximates US Census (2000 US Census), which 
enhances its likelihood of being generalizable.
Second, the PDSQ is a screening instrument, 
rather than a reference standard diagnostic instru-
ment, and it has not been validated in primary 
care settings. Although we set parameters to yield 
90% specifi city relative to a reference standard, our 
estimates could be biased toward either over- or 
underreporting. Indeed, our fi ndings may underreport 
psychiatric comorbidity. While broadly inclusive, our 
selection criteria excluded patients with psychotic 
symptoms and a primary diagnosis of obsessive-com-
pulsive disorder or eating disorders. Still our main 
fi ndings regarding the similar rates of comorbid anxi-
ety disorders are likely accurate; the PDSQ has shown 
excellent test characteristics as a screen for anxiety 
disorders comorbid with major depression relative to 
the reference standard SCID,50,51 and as noted earlier, 
the rates of comorbid anxiety disorders are consistent 
with earlier published reports. 
Third, these fi ndings do not apply to those clinic 
patients who are not identifi ed as depressed, a well-
described group who may represent as much as 50% of 
those depressed in primary care settings.52-55 Rather, 
our results apply to those populations of primary 
care and specialty care settings who are identifi ed as 
being depressed. This group remains at marked risk of 
not receiving adequate treatment regardless of treat-
ment location. In a nationally representative sample of 
the US population, Kessler et al found that of those 
identifi ed as needing treatment for depression, only 
40% receive minimally adequate treatment, with defi -
ciencies noted in both primary care and specialty care 
settings.56 Similarly, in a nationally representative sam-
ple of adults initiating a new episode of antidepressant 
treatment for depression, Olfson et al found that a sub-
stantial proportion of the patients discontinued antide-
pressant therapy during the fi rst 30 days (42.4%).57 
Finally, these data are hypothesis generating in 
nature. We conducted multiple statistical compari-
sons without Bonferroni correction for multiple tests, 
which increases the likelihood of fi nding chance asso-
ciations. Our fi ndings identifi ed very few such associa-
tions, however, and most of those identifi ed were of 
questionable clinical importance. For example, the site 
differences found with our health-related quality-of-
life measures (SF-12 and WSAS) fell somewhat short 
of either the approximately one half a standard devi-
ation58 or standard error of measurement59 thresholds 
that have been suggested as a clinically meaningful 
“minimally important difference.” We hope these 
results serve to stimulate further research that directly 
compares depressive illness in primary care and psy-
chiatric outpatient sites. 
The similarity in symptoms between the 2 set-
tings has a number of implications. First, it suggests 
that, given similar populations to begin with, clinical 
trial results from primary care and specialty care may 
be equivalent, and results may be more generaliz-
able between settings. Indeed, the initial outcomes 
report from STAR*D reported no difference by 
setting.60 Whether these outcomes differ by setting 
for resistant depressions with subsequent treatments 
will be reported. Second, the similarity of symptoms 
may refl ect the reality of US contemporary primary 
care practice. As community mental health clinics 
move toward restricting treatment to more severely 
mentally ill patients (those with psychotic and bipolar 
illness) and primary care doctors have better resources 
to manage depressive illness, and with guidelines now 
recommending screening of depression in primary 
care,3,4 the treatment of MDD increasingly falls upon 
primary care physicians. 
Evidence-based management approaches to depres-
sion that increase chances of remission and response in 
primary care clearly exist.61-63 Still, this burden is not 
light. In this large, broadly inclusive sample, the risk 
factors for chronic and recurrent depressive illness—
including a long period of depressive illness, a history 
of depressive episodes, suicidal ideation, and psychiat-
ric comorbidity—were frequently present. This fi nding 
indicates a clear risk for treatment resistance and high-
lights the need for aggressive management strategies in 
both settings.
To read or post commentaries in response to this article, see it 
online at http://www.annfammed.org/cgi/content/full/5/2/126. 
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